NASDAQ:ATEC - Alphatec Stock Price, News, & Analysis

$4.39
-0.19 (-4.15 %)
(As of 06/19/2019 08:00 AM ET)
Today's Range
$4.36
Now: $4.39
$4.60
50-Day Range
$3.5650
MA: $4.13
$4.72
52-Week Range
$1.18
Now: $4.39
$4.85
Volume276,600 shs
Average Volume191,091 shs
Market Capitalization$205.72 million
P/E RatioN/A
Dividend YieldN/A
Beta1.49
Alphatec Holdings, Inc, a medical technology company, focuses on the design, development, and promotion of products for the surgical treatment of spine disorders. Its product portfolio and pipeline address the cervical, thoracolumbar, and intervertebral regions of the spine; and cover various spinal disorders and surgical procedures. The company offers MIS products consisting of Battalion Lateral Spacer System and Squadron Lateral Retractor, Illico Minimally Invasive Surgery System, and BridgePoint Spinous Process Fixation System; and fixation products, such as Arsenal Screw System and Zodiac Spinal Fixation Systems. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ATEC
CUSIP02081G10
Phone760-431-9286

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$91.69 million
Book Value$0.41 per share

Profitability

Net Income$-28,980,000.00

Miscellaneous

Employees195
Market Cap$205.72 million
Next Earnings Date8/1/2019 (Estimated)
OptionableNot Optionable

Receive ATEC News and Ratings via Email

Sign-up to receive the latest news and ratings for ATEC and its competitors with MarketBeat's FREE daily newsletter.

Alphatec (NASDAQ:ATEC) Frequently Asked Questions

What is Alphatec's stock symbol?

Alphatec trades on the NASDAQ under the ticker symbol "ATEC."

How were Alphatec's earnings last quarter?

Alphatec Holdings Inc (NASDAQ:ATEC) released its earnings results on Thursday, May, 9th. The medical technology company reported ($0.20) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.20). The medical technology company had revenue of $24.56 million for the quarter, compared to analysts' expectations of $24 million. Alphatec had a negative return on equity of 156.32% and a negative net margin of 42.16%. View Alphatec's Earnings History.

When is Alphatec's next earnings date?

Alphatec is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for Alphatec.

What price target have analysts set for ATEC?

1 brokers have issued 12 month price objectives for Alphatec's stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate Alphatec's stock price to reach $4.00 in the next year. This suggests that the stock has a possible downside of 8.9%. View Analyst Price Targets for Alphatec.

What is the consensus analysts' recommendation for Alphatec?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alphatec in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alphatec.

What are Wall Street analysts saying about Alphatec stock?

Here are some recent quotes from research analysts about Alphatec stock:
  • 1. According to Zacks Investment Research, "Alphatec Holdings, Inc. is a medical technology company focused on the design, development, manufacturing and marketing of products for the surgical treatment of spine disorders. The Company's principal product offering includes a variety of spinal implant products and systems consisted of components, such as spine screws and rods, spinal spacers, plates, and various biologics offerings. Alphatec Holdings, Inc. is headquartered in Carlsbad, California. " (5/13/2019)
  • 2. HC Wainwright analysts commented, "We are maintaining our Buy rating of ATEC and our 12-month price target of $4.00 per diluted share. We derive our price target based on: 1) an EV-to-sales multiple analysis assuming 10% discount rate and using a 3.0x multiple on projected 2025 sales of $244M; and 2) a discounted cash flow analysis using the projected free cash flow to the firm through 2025 and assuming a 10% discount rate and 3% terminal growth rate. Using the average of the two methods, we arrive at a 12-month price target of $3.87 per share, which we round to $4.00." (1/14/2019)

Has Alphatec been receiving favorable news coverage?

Media coverage about ATEC stock has trended somewhat negative on Wednesday, InfoTrie reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Alphatec earned a news sentiment score of -1.3 on InfoTrie's scale. They also gave press coverage about the medical technology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Alphatec.

Who are some of Alphatec's key competitors?

What other stocks do shareholders of Alphatec own?

Who are Alphatec's key executives?

Alphatec's management team includes the folowing people:
  • Mr. Patrick S. Miles, Exec. Chairman & CEO (Age 53)
  • Mr. Craig E. Hunsaker, Exec. VP of People & Culture, Corp. Sec. and Gen. Counsel (Age 55)
  • Mr. Terry M. Rich, Consultant (Age 51)
  • Mr. Jeffrey P. Rydin, Director (Age 52)
  • Mr. Jeffrey G. Black, Exec. VP & CFO (Age 50)

Who are Alphatec's major shareholders?

Alphatec's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Penn Capital Management Co. Inc. (1.02%), Royce & Associates LP (0.62%) and Spark Investment Management LLC (0.12%). Company insiders that own Alphatec stock include Brian Snider, Craig E Hunsaker, Evan Bakst, Jeffrey G Black, Kelli Mari Howell and Terry Rich. View Institutional Ownership Trends for Alphatec.

Which major investors are selling Alphatec stock?

ATEC stock was sold by a variety of institutional investors in the last quarter, including Spark Investment Management LLC. View Insider Buying and Selling for Alphatec.

Which major investors are buying Alphatec stock?

ATEC stock was bought by a variety of institutional investors in the last quarter, including Penn Capital Management Co. Inc. and Royce & Associates LP. Company insiders that have bought Alphatec stock in the last two years include Brian Snider, Evan Bakst, Jeffrey G Black, Kelli Mari Howell and Terry Rich. View Insider Buying and Selling for Alphatec.

How do I buy shares of Alphatec?

Shares of ATEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alphatec's stock price today?

One share of ATEC stock can currently be purchased for approximately $4.39.

How big of a company is Alphatec?

Alphatec has a market capitalization of $205.72 million and generates $91.69 million in revenue each year. The medical technology company earns $-28,980,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Alphatec employs 195 workers across the globe.View Additional Information About Alphatec.

What is Alphatec's official website?

The official website for Alphatec is http://www.atecspine.com/.

How can I contact Alphatec?

Alphatec's mailing address is 5818 EL CAMINO REAL, CARLSBAD CA, 92008. The medical technology company can be reached via phone at 760-431-9286 or via email at [email protected]


MarketBeat Community Rating for Alphatec (NASDAQ ATEC)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  208 (Vote Outperform)
Underperform Votes:  247 (Vote Underperform)
Total Votes:  455
MarketBeat's community ratings are surveys of what our community members think about Alphatec and other stocks. Vote "Outperform" if you believe ATEC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATEC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2019 by MarketBeat.com Staff

Featured Article: Forex

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel